STAAR Surgical Company
STAA Small CapHealthcare · Medical Instruments & Supplies
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
STAAR Surgical Company en bref
STAAR Surgical Company (STAA) is currently trading at 25,39 € with a market capitalization of 1,3 Md €. The 52-week range spans from 13,59 € to 31,27 €; the current price is 18.8% below the yearly high. Year-over-year revenue growth stands at +119.6%.
💰 Dividende
STAAR Surgical Company currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
9 analystes évaluent STAAR Surgical Company (STAA) au consensus : None. L'objectif de cours moyen est de 25,87 €, soit un potentiel de +1.88% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,05 € à 34,87 €.
STAAR Surgical Company : la thèse d'investissement en détail
STAAR Surgical Company (STAA) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 119.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 76.89%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 22.1% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
With a PEG ratio of 0.76, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 90.5x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 119.6% sur un an
- Marge brute élevée de 76.89% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 10.58)
- –Actuellement non rentable
- –Positions vendeuses élevées (22.1%)
- –Free cash flow négatif
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to market-like volatility, elevated short interest (22.1%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy STAAR Surgical Company?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news